PMID- 2598189
OWN - NLM
STAT- MEDLINE
DCOM- 19900130
LR  - 20240426
IS  - 0340-7004 (Print)
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Linking)
VI  - 30
IP  - 4
DP  - 1989
TI  - Augmentative effect of Nocardia rubra cell-wall skeleton on the induction of 
      human lymphokine-activated killer (LAK) cells by the production of LAK cell 
      helper factor(s).
PG  - 195-204
AB  - Nocardia rubra cell wall skeleton (N-CWS) was found to synergistically augment 
      lymphokine-activated killer (LAK) cell generation from human peripheral blood 
      mononuclear cells (PBMC) in the presence of a suboptimal dose of recombinant 
      interleukin-2 (rIL-2). N-CWS increased the number of PBMC expressing IL-2 
      receptor on their surfaces, and the presence of N-CWS at the early stage of the 
      culture period was essential for the exertion of its augmentative activity on the 
      LAK induction. The predominant phenotype of LAK precursor cells responding to 
      N-CWS and rIL-2 was CD3- CD16+. Culture supernatant from N-CWS-stimulated PBMC 
      was found to act as a substitute for N-CWS in the induction of LAK generation in 
      the presence of rIL-2, suggesting that these cells produced a factor capable of 
      augmenting LAK cell induction (LAK helper factor, LHF). LHF was found to have a 
      molecular mass of 29 kDa by gel filtration, and could also function as a killer 
      helper factor to augment allo-antigen-specific cytotoxic T lymphocyte generation 
      from human peripheral blood T cells as well as murine thymocytes. LHF showed no 
      species specificity, indicating that it is different from IL-4. The enhancing 
      activity of LHF was not neutralized with anti-TNF alpha, anti-IL-1 alpha, or 
      anti-IL-1 beta antibodies. Furthermore, no tumor necrosis factor-alpha (TNF 
      alpha), TNF beta, IL-1 alpha, beta, IL-2, IL-5, IL-6 or interferon activity was 
      detected in semi-purified LHF during enzyme-linked immunosorbant assay and 
      biological assays. The present findings indicate that LHF produced from 
      N-CWS-stimulated PBMC is a molecule distinct from TNF alpha, TNF beta, 
      interferon, IL-1, -2, -4, -5, and -6, and suggest that LHF might be a novel 
      lymphokine involved in LAK generation.
FAU - Shirasaka, T
AU  - Shirasaka T
AD  - 3rd Department of Internal Medicine, Osaka University Medical School, Japan.
FAU - Kawase, I
AU  - Kawase I
FAU - Okada, M
AU  - Okada M
FAU - Kitahara, M
AU  - Kitahara M
FAU - Ikeda, T
AU  - Ikeda T
FAU - Komuta, K
AU  - Komuta K
FAU - Hosoe, S
AU  - Hosoe S
FAU - Yokota, S
AU  - Yokota S
FAU - Masuno, T
AU  - Masuno T
FAU - Kishimoto, S
AU  - Kishimoto S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Cell Wall Skeleton)
RN  - 0 (Interleukin-2)
RN  - 0 (Interleukins)
RN  - 0 (Lymphokines)
RN  - 0 (Mucoproteins)
RN  - 0 (Receptors, Interleukin-2)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (cell wall skeleton, Nocardia)
SB  - IM
MH  - Adjuvants, Immunologic/*pharmacology
MH  - Animals
MH  - *Cell Wall Skeleton
MH  - Immunotherapy
MH  - Interleukin-2/pharmacology
MH  - Interleukins/analysis
MH  - Killer Cells, Lymphokine-Activated/*drug effects/immunology
MH  - Lymphocyte Activation/drug effects
MH  - Lymphokines/analysis/*biosynthesis/isolation & purification
MH  - Mice
MH  - Mucoproteins/*pharmacology
MH  - Phenotype
MH  - Receptors, Interleukin-2/biosynthesis
MH  - T-Lymphocytes, Cytotoxic/drug effects
MH  - Tumor Necrosis Factor-alpha/analysis
PMC - PMC11038045
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
PMCR- 1989/07/01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
PHST- 1989/07/01 00:00 [pmc-release]
AID - BF01665005 [pii]
AID - 10.1007/BF01665005 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 1989;30(4):195-204. doi: 10.1007/BF01665005.